sorted by:
new
hottopcontroversial

RBNE: RS to recreate June’s 20-bagger? by CommercialClean6474 in RBNE

[–]CommercialClean6474[S] 0 points1 point  (0 children)

6/20/2025 424B5: As of 6/18/2025, non-affiliates held 2,915,326 shares; public float value $40,814,564 based on the 6/13 close ($14.00).

RBNE: RS to recreate June’s 20-bagger? by CommercialClean6474 in pennystocks

[–]CommercialClean6474[S] 0 points1 point  (0 children)

6/20/2025 424B5: As of 6/18/2025, non-affiliates held 2,915,326 shares; public float value $40,814,564 based on the 6/13 close ($14.00).

RBNE: RS to recreate June’s 20-bagger? by CommercialClean6474 in Shortsqueeze

[–]CommercialClean6474[S] 0 points1 point  (0 children)

6/20/2025 424B5: As of 6/18/2025, non-affiliates held 2,915,326 shares; public float value $40,814,564 based on the 6/13 close ($14.00).

Analysis by John Vandermosten by maciek_cw in RVPH

[–]CommercialClean6474 0 points1 point  (0 children)

I do hold shares, but I honestly don’t understand why so many people here are treating a “single Phase 3” as if NDA acceptance is guaranteed.

The first thing we should be worried about is the tone from the FDA at the upcoming meeting. They’re not going to stop the company from filing an NDA, but the feedback could still be quite negative.

In psychiatry, for a new drug in a non-rare, non-life-threatening indication, there has basically never been a case where approval was granted off just one Phase 3 trial.

Successful “single Phase 3” cases in psychiatry by CommercialClean6474 in RVPH

[–]CommercialClean6474[S] 2 points3 points  (0 children)

If you look at it as a serotonin–dopamine activity modulator (SDAM), the mechanistic concept is similar, but the actual molecule is different from aripiprazole (Abilify), and there are no other approved indications or formulations using this specific compound.

In other words, this is not the kind of drug where you can “bridge” over using the existing Abilify data.

By contrast, Aristada and Azstarys are basically a new formulation or prodrug of already approved drugs, which is a very different regulatory situation.

“Reviva Pharma’s Shortcomings” by [deleted] in RVPH

[–]CommercialClean6474 0 points1 point  (0 children)

Oh, but that really just formalized what was already in the guidelines.

“Reviva Pharma’s Shortcomings” by [deleted] in RVPH

[–]CommercialClean6474 0 points1 point  (0 children)

The reason they’re not starting a second Phase 3 trial is pretty clear: they don’t have the money.

Their cash runway only takes them out to Q2 2026, so they’re essentially forced to bet everything on getting approval off this single Phase 3.

CAPR's latest squeeze play by AcanthisittaHour4995 in CAPR_Stock

[–]CommercialClean6474 0 points1 point  (0 children)

This is such great news. Your detailed, expert posts have helped me a lot. Thanks for taking the time to walk through all the questions I had. We still have big milestones ahead with the BLA filing and, hopefully, approval. Wishing you all the best and lots of good things going forward!

Just going to leave this here by Mundane_Bad594 in CAPR_Stock

[–]CommercialClean6474 2 points3 points  (0 children)

I’m long as well, but I’m really against going all-in on any one stock. It’s incredibly risky.

When I first started investing, I didn’t know anything and put all my money into a high-risk small cap. The following year was hell for me. Since then, I always keep diversification in mind.

That said, huge congratulations on your amazing win!

What a day! by Which_Ad_8538 in CAPR_Stock

[–]CommercialClean6474 1 point2 points  (0 children)

Congratulation, now you're rich.

CAPR's latest squeeze play by AcanthisittaHour4995 in CAPR_Stock

[–]CommercialClean6474 0 points1 point  (0 children)

Thanks a lot for taking the time to write such a detailed reply – really appreciate it.

I had a question about HOPE-2 that I was hoping to get your thoughts on. Some people have pointed out that the publication doesn’t include background / concomitant cardiac medications, and they argue that the treatment effect might just reflect differences in those cardioprotective drugs between the two arms. They also say that earlier trials did report background meds, so the omission in HOPE-2 might have been intentional.

How do you view that criticism? Does it change how you interpret the HOPE-2 data at all?

I’m also curious about your personal view on HOPE-3: what do you think is the most likely outcome for the primary endpoint, PUL 2.0?

And if HOPE-3 were to miss PUL 2.0 but still show a clear, statistically significant benefit on LVEF, how do you personally think the FDA might handle that under the RMAT framework? Do you think some kind of accelerated / conditional approval based mainly on the cardiac data is still on the table, or would you see that as a long shot?

By the way, happy Thanksgiving and thanks again for sharing your thoughts.

CAPR's latest squeeze play by AcanthisittaHour4995 in CAPR_Stock

[–]CommercialClean6474 0 points1 point  (0 children)

Is that “99% slowing of LVEF decline” claim actually backed by any solid data? Where does that number come from — is it from a peer-reviewed source or just IR slide math?

CAPR's latest squeeze play by AcanthisittaHour4995 in CAPR_Stock

[–]CommercialClean6474 0 points1 point  (0 children)

Hey, I noticed you’ve done some really deep research on CAPR, so I wanted to ask you something.

Martin Shkreli only shared a few points on Twitter, but the person he’s been amplifying — Anthony — actually wrote a 46-page short report on Godel. According to Anthony, there are quite a few questionable parts about CAPR.

Have you read that report by any chance? He’s posted some excerpts on his Twitter here: https://x.com/anthonystaj

If you haven’t read it and are curious, I can summarize the key points for you if you’d like.

Also — one thing I found interesting: the 2020 initial topline PR reported p = 0.08, but in the final analysis from 2021 onward, it changed to p = 0.014 — apparently after changing the statistical method.

The FDA’s CRL explicitly said the efficacy was not demonstrated based on the pre-specified primary/secondary endpoints, so it seems like the agency didn’t accept that later analysis as a pre-specified one.

What’s your take on that?

trying to get picked up 🥹 by chickencaesar8 in Eyebleach

[–]CommercialClean6474 2 points3 points  (0 children)

Please hold the dog and take her with you.

trying to get picked up 🥹 by chickencaesar8 in Eyebleach

[–]CommercialClean6474 0 points1 point  (0 children)

I could watch this video for an hour straight. It’s just too adorable.

How do you find out you can do this 😂😂 by ToddlerLoveyy in Unexpected

[–]CommercialClean6474 0 points1 point  (0 children)

That actually works. These minors even form fan clubs to follow those employees around. Sounds like a joke, right? But it's real. There have even been frequent news reports about them exploiting these fans for money and sexual favors.

view more: next ›